Australian Clinical Labs (ASX:ACL) will benefit from high levels of covid testing in Australia.

Damstra shares are trading 13% higher after the company reported record revenue in the fourth quarter of FY 2021.

IntelliHR (ASX: IHR) share price have been a rollercoaster over the last year, but the IntelliHR quarterly results show good organic growth.

Eroad has more success in New Zealand than the USA, but acquiring Coretex may well be the best move to drive international growth faster.

Objective Corporation (ASX:OCL) has reported record revenue, record profit, and record annualised recurring revenue, in FY 2021. But is its valuation too punchy?

The Xref (ASX:XF1) share price has gained over 16% on a record result which sees the company achieve free cash flow breakeven in FY2021.

My high conviction holdings drove my portfolio returns as usual, but some are better value than others, at current prices.

I’m pleased to have soundly beat the market in FY 2021, but there are a number of important lessons I can take from my performance…

One director of this boring dividend payer just bought a fair chunk of shares at slightly above the current price.

The Redbubble (ASX: RBL) share price gained over 500% during the pandemic, but the business model is badly misunderstood.

IntelliHR (ASX: IHR) looks to have reached an inflection point with its revenue growth, but it’s a long way from profitability. Here’s why it’s worth watching.

Medical Developments International (ASX:MVP) shares look attractive at current prices given the potential for significant Penthrox sales growth.

Macquarie notes that Sezzle’s Appstore ranking has improved, but their analysis barely scratches the surface. Are Sezzle (ASX:SZL) shareholders in the dark?

These three stocks have seen insider buying and have decent prospects in the next few years.

The Little Book of Behavioural Investing by James Montier stresses the importance of being process focused as opposed to outcome focused…

Appen (ASX: APX) shares are a potentially interesting investment, but investors should focus on the key drivers of the business, not EBITDA multiples.

The EML Payments (ASX:EML) share price is down around 34% on regulatory concerns that could undermine its reputation globally.

Volatile markets are seeing growth stocks crash, value stocks climb, and dogecoin attract new suckers like iron filings to a magnet.

One of the easiest ways to get started as an ethical investor is to buy one of these ASX listed ethical ETFs.

My original Whispir (ASX: WSP) thesis has played out nicely but I no longer find the risk vs reward attractive.